FFP 104

Drug Profile

FFP 104

Alternative Names: FFP104

Latest Information Update: 08 Feb 2016

Price : $50

At a glance

  • Originator FF Pharma
  • Class Antifibrotics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Primary biliary cirrhosis

Most Recent Events

  • 01 Jan 2016 Phase-II clinical trials in Crohn's disease in Netherlands, Belgium (IV) (NCT02465944)
  • 13 Jun 2015 FF Pharmaceuticals plans a phase I/II in Crohn's disease in Netherlands (NCT02465944)
  • 01 May 2015 Phase II clinical trials in Primary biliary cirrhosis in Netherlands (Parenteral) (NCT02193360)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top